Caffeine increases striatal dopamine D2/D3 receptor availability in the human brain

Translational Psychiatry

Volumn 5, Issue 4, 2015, Pages

  Volkow, N D ^a   Wang, G J ^a   Logan, J ^b   Alexoff, D ^b   Fowler, J S ^b   Thanos, P K ^b   Wong, C ^a   Casado, V ^c   Ferre, S ^d   Tomasi, D ^a  

^a NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM   (United States)

^b BROOKHAVEN NATIONAL LABORATORY   (United States)

^c UNIVERSITY OF BARCELONA   (Spain)

^d NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CAFFEINE; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; PLACEBO; RACLOPRIDE C 11; RADIOLIGAND; ADENOSINE A2A RECEPTOR; CENTRAL STIMULANT AGENT; DOPAMINE; DOPAMINE RECEPTOR BLOCKING AGENT; DRD2 PROTEIN, HUMAN; DRD3 PROTEIN, HUMAN; RACLOPRIDE;

ADULT; ALERTNESS; ARTICLE; BRAIN; CONTROLLED STUDY; CORPUS STRIATUM; HUMAN; HUMAN EXPERIMENT; HUMAN TISSUE; MALE; NORMAL HUMAN; POSITRON EMISSION TOMOGRAPHY; PUTAMEN; SELF REPORT; VENTRAL STRIATUM; AFFECT; AROUSAL; BLOOD PRESSURE; CAUDATE NUCLEUS; DIAGNOSTIC IMAGING; DRUG EFFECTS; HEART RATE; METABOLISM; MIDDLE AGED; NEOSTRIATUM;

ADULT; AFFECT; AROUSAL; BLOOD PRESSURE; BRAIN; CAFFEINE; CAUDATE NUCLEUS; CENTRAL NERVOUS SYSTEM STIMULANTS; DOPAMINE; DOPAMINE ANTAGONISTS; HEART RATE; HUMANS; MALE; MIDDLE AGED; NEOSTRIATUM; POSITRON-EMISSION TOMOGRAPHY; PUTAMEN; RACLOPRIDE; RECEPTOR, ADENOSINE A2A; RECEPTORS, DOPAMINE D2; RECEPTORS, DOPAMINE D3; VENTRAL STRIATUM;

EID: 84990876503     PISSN: None     EISSN: 21583188     Source Type: Journal    
DOI: 10.1038/tp.2015.46     Document Type: Article

References (58)

1. Mitchell DC, Knight CA, Hockenberry J, Teplansky R, Hartman TJ. Beverage caffeine intakes in the U.S. Food Chem Toxicol 2014; 63: 136-142.
2. Cardenas L, Houle S, Kapur S, Busto UE. Oral D-amphetamine causes prolonged displacement of [11C]raclopride as measured by PET. Synapse 2004; 51: 27-31.
3. Volkow ND, Fowler JS, Logan J, Alexoff D, Zhu W, Telang F et al. Effects of modafinil on dopamine and dopamine transporters in the male human brain: Clinical implications. JAMA 2009; 301: 1148-1154.
4. Volkow ND, Wang G, Fowler JS, Logan J, Gerasimov M, Maynard L et al. Therapeutic doses of oral methylphenidate significantly increase extracellular dopamine in the human brain. J Neurosci 2001; 21: RC121.
5. Volkow ND, Tomasi D, Wang GJ, Telang F, Fowler JS, Logan J et al. Evidence that sleep deprivation downregulates dopamine D2R in ventral striatum in the human brain. J Neurosci 2012; 32: 6711-6717.
6. Wisor JP, Nishino S, Sora I, Uhl GH, Mignot E, Edgar DM. Dopaminergic role in stimulant-induced wakefulness. J Neurosci 2001; 21: 1787-1794.
7. Abi-Dargham A, Kegeles LS, Martinez D, Innis RB, Laruelle M. Dopamine mediation of positive reinforcing effects of amphetamine in stimulant naive healthy volunteers: Results from a large cohort. Eur Neuropsychopharmacol 2003; 13: 459-468.
8. Nguyen TL, Tian YH, You IJ, Lee SY, Jang CG. Modafinil-induced conditioned place preference via dopaminergic system in mice. Synapse 2011; 65: 733-741.
9. Volkow ND, Wang GJ, Fowler JS, Logan J, Gatley SJ, Wong C et al. Reinforcing effects of psychostimulants in humans are associated with increases in brain dopamine and occupancy of D(2) receptors. J Pharmacol Exp Ther 1999; 291: 409-415.
10. Wuo-Silva R, Fukushiro DF, Borcoi AR, Fernandes HA, Procopio-Souza R, Hollais AW et al. Addictive potential of modafinil and cross-sensitization with cocaine: A pre-clinical study. Addict Biol 2011; 16: 565-579.
11. Banerjee D, Vitiello MV, Grunstein RR. Pharmacotherapy for excessive daytime sleepiness. Sleep Med Rev 2004; 8: 339-354.
12. Chen JF, Xu K, Petzer JP, Staal R, Xu YH, Beilstein M et al. Neuroprotection by caffeine and A(2 A) adenosine receptor inactivation in a model of Parkinson's disease. J Neurosci 2001; 21: RC143.
13. El Yacoubi M, Ledent C, Menard JF, Parmentier M, Costentin J, Vaugeois JM. The stimulant effects of caffeine on locomotor behaviour in mice are mediated through its blockade of adenosine A(2A) receptors. Br J Pharmacol 2000; 129: 1465-1473.
14. Huang ZL, Qu WM, Eguchi N, Chen JF, Schwarzschild MA, Fredholm BB et al. Adenosine A2A, but not A1, receptors mediate the arousal effect of caffeine. Nat Neurosci 2005; 8: 858-859.
15. Lazarus M, Shen HY, Cherasse Y, Qu WM, Huang ZL, Bass CE et al. Arousal effect of caffeine depends on adenosine A2A receptors in the shell of the nucleus accumbens. J Neurosci 2011; 31: 10067-10075.
16. Ferre S, Ciruela F, Woods AS, Lluis C, Franco R. Functional relevance of neurotransmitter receptor heteromers in the central nervous system. Trends Neurosci 2007; 30: 440-446.
17. Azdad K, Gall D, Woods AS, Ledent C, Ferre S, Schiffmann SN. Dopamine D2 and adenosine A2A receptors regulate NMDA-mediated excitation in accumbens neurons through A2A-D2 receptor heteromerization. Neuropsychopharmacology 2009; 34: 972-986.
18. Trifilieff P, Rives ML, Urizar E, Piskorowski RA, Vishwasrao HD, Castrillon J et al. Detection of antigen interactions ex vivo by proximity ligation assay: Endogenous dopamine D2-adenosine A2A receptor complexes in the striatum. Biotechniques 2011; 51: 111-118.
19. Ferre S. Role of the central ascending neurotransmitter systems in the psychostimulant effects of caffeine. J Alzheimers Dis 2010; 20(Suppl 1): S35-S49.
20. Fredholm BB, Battig K, Holmen J, Nehlig A, Zvartau EE. Actions of caffeine in the brain with special reference to factors that contribute to its widespread use. Pharmacol Rev 1999; 51: 83-133.
21. Solinas M, Ferre S, You ZB, Karcz-Kubicha M, Popoli P, Goldberg SR. Caffeine induces dopamine and glutamate release in the shell of the nucleus accumbens. J Neurosci 2002; 22: 6321-6324.
22. Acquas E, Tanda G, Di Chiara G. Differential effects of caffeine on dopamine and acetylcholine transmission in brain areas of drug-naive and caffeinepretreated rats. Neuropsychopharmacology 2002; 27: 182-193.
23. De Luca MA, Bassareo V, Bauer A, Di Chiara G. Caffeine and accumbens shell dopamine. J Neurochem 2007; 103: 157-163.
24. Kaasinen V, Aalto S, Nagren K, Rinne JO. Dopaminergic effects of caffeine in the human striatum and thalamus. Neuroreport 2004; 15: 281-285.
25. Volkow ND, Wang GJ, Fowler JS, Logan J, Schlyer D, Hitzemann R et al. Imaging endogenous dopamine competition with [11C]raclopride in the human brain. Synapse 1994; 16: 255-262.
26. Wang G-J, Volkow ND, Hitzemann RJ, Wong C, Angrist B, Burr G et al. Behavioral and cardiovascular effects of intravenous methylphenidate in normal subjects and cocaine abusers. Eur Addict Res 1997; 3: 49-54.
27. Fischman MW, Foltin RW. Utility of subjective-effects measurements in assessing abuse liability of drugs in humans. Br J Addict 1991; 86: 1563-1570.
28. Liguori A, Hughes JR, Grass JA. Absorption and subjective effects of caffeine from coffee, cola and capsules. Pharmacol Biochem Behav 1997; 58: 721-726.
29. Tanaka E. Simultaneous determination of caffeine and its primary demethylated metabolites in human plasma by high-performance liquid chromatography. J Chromatogr 1992; 575: 311-314.
30. Volkow ND, Fowler JS, Wang GJ, Hitzemann R, Logan J, Schlyer DJ et al. Decreased dopamine D2 receptor availability is associated with reduced frontal metabolism in cocaine abusers. Synapse 1993; 14: 169-177.
31. Lelo A, Birkett DJ, Robson RA, Miners JO. Comparative pharmacokinetics of caffeine and its primary demethylated metabolites paraxanthine, theobromine and theophylline in man. Br J Clin Pharmacol 1986; 22: 177-182.
32. Friston KJ, Holmes AP, Poline JB, Grasby PJ, Williams SC, Frackowiak RS et al. Analysis of fMRI time-series revisited. Neuroimage 1995; 2: 45-53.
33. Logan J, Fowler JS, Volkow ND, Wang GJ, Ding YS, Alexoff DL. Distribution volume ratios without blood sampling from graphical analysis of PET data. J Cereb Blood Flow Metab 1996; 16: 834-840.
34. Volkow ND, Wang GJ, Fowler JS, Tomasi D, Telang F. Addiction: Beyond dopamine reward circuitry. Proc Natl Acad Sci USA 2011; 108: 15037-15042.
35. Tzourio-Mazoyer N, Landeau B, Papathanassiou D, Crivello F, Etard O, Delcroix N et al. Automated anatomical labeling of activations in SPM using a macroscopic anatomical parcellation of the MNI MRI single-subject brain. Neuroimage 2002; 15: 273-289.
36. Martinez D, Slifstein M, Broft A, Mawlawi O, Hwang DR, Huang Y et al. Imaging human mesolimbic dopamine transmission with positron emission tomography. Part II: Amphetamine-induced dopamine release in the functional subdivisions of the striatum. J Cereb Blood Flow Metab 2003; 23: 285-300.
37. Iizuka Y, Sei Y, Weinberger DR, Straub RE. Evidence that the BLOC-1 protein dysbindin modulates dopamine D2 receptor internalization and signaling but not D1 internalization. J Neurosci 2007; 27: 12390-12395.
38. Bartlett SE, Enquist J, Hopf FW, Lee JH, Gladher F, Kharazia V et al. Dopamine responsiveness is regulated by targeted sorting of D2 receptors. Proc Natl Acad Sci USA 2005; 102: 11521-11526.
39. Ginovart N, Wilson AA, Hussey D, Houle S, Kapur S. D2-receptor upregulation is dependent upon temporal course of D2-occupancy: A longitudinal [11C]-raclopride PET study in cats. Neuropsychopharmacology 2009; 34: 662-671.
40. Xu ZC, Ling G, Sahr RN, Neal-Beliveau BS. Asymmetrical changes of dopamine receptors in the striatum after unilateral dopamine depletion. Brain Res 2005; 1038: 163-170.
41. Li Y, Roy BD, Wang W, Zhang L, Zhang L, Sampson SB et al. Identification of two functionally distinct endosomal recycling pathways for dopamine D(2) receptor. J Neurosci 2012; 32: 7178-7190.
42. Hillion J, Canals M, Torvinen M, Casado V, Scott R, Terasmaa A et al. Coaggregation, cointernalization, and codesensitization of adenosine A2A receptors and dopamine D2 receptors. J Biol Chem 2002; 277: 18091-18097.
43. Borroto-Escuela DO, Romero-Fernandez W, Tarakanov AO, Ciruela F, Agnati LF, Fuxe K. On the existence of a possible A2A-D2-beta-Arrestin2 complex: A2A agonist modulation of D2 agonist-induced beta-arrestin2 recruitment. J Mol Biol 2011; 406: 687-699.
44. Huang L, Wu DD, Zhang L, Feng LY. Modulation of A(2)a receptor antagonist on D (2) receptor internalization and ERK phosphorylation. Acta Pharmacol Sin 2013; 34: 1292-1300.
45. Biaggioni I, Paul S, Puckett A, Arzubiaga C. Caffeine and theophylline as adenosine receptor antagonists in humans. J Pharmacol Exp Ther 1991; 258: 588-593.
46. Schwierin B, Borbely AA, Tobler I. Effects of N6-cyclopentyladenosine and caffeine on sleep regulation in the rat. Eur J Pharmacol 1996; 300: 163-171.
47. Ferre S, Ciruela F, Borycz J, Solinas M, Quarta D, Antoniou K et al. Adenosine A1-A2A receptor heteromers: New targets for caffeine in the brain. Front Biosci 2008; 13: 2391-2399.
48. Dassesse D, Massie A, Ferrari R, Ledent C, Parmentier M, Arckens L et al. Functional striatal hypodopaminergic activity in mice lacking adenosine A(2A) receptors. J Neurochem 2001; 78: 183-198.
49. Volkow ND, Wang GJ, Fowler JS, Tomasi D. Addiction circuitry in the human brain. Annu Rev Pharmacol Toxicol 2012; 52: 321-336.
50. Dews PB, O'Brien CP, Bergman J. Caffeine: Behavioral effects of withdrawal and related issues. Food Chem Toxicol 2002; 40: 1257-1261.
51. Levant B, Grigoriadis DE, De Souza EB. Relative affinities of dopaminergic drugs at dopamine D2 and D3 receptors. Eur J Pharmacol 1995; 278: 243-247.
52. Searle G, Beaver JD, Comley RA, Bani M, Tziortzi A, Slifstein M et al. Imaging dopamine D3 receptors in the human brain with positron emission tomography, [11C]PHNO, and a selective D3 receptor antagonist. Biol Psychiatry 2010; 68: 392-399.
53. Cameron OG, Modell JG, Hariharan M. Caffeine and human cerebral blood flow: A positron emission tomography study. Life Sci 1990; 47: 1141-1146.
54. Vidyasagar R, Greyling A, Draijer R, Corfield DR, Parkes LM. The effect of black tea and caffeine on regional cerebral blood flow measured with arterial spin labeling. J Cereb Blood Flow Metab 2013; 33: 963-968.
55. Kodaka F, Ito H, Kimura Y, Fujie S, Takano H, Fujiwara H et al. Test-retest reproducibility of dopamine D2/3 receptor binding in human brain measured by PET with [11C]MNPA and [11C]raclopride. Eur J Nucl Med Mol Imaging 2013; 40: 574-579.
56. Volkow ND, Fowler JS, Wang GJ, Dewey SL, Schlyer D, MacGregor R et al. Reproducibility of repeated measures of carbon-11-raclopride binding in the human brain. J Nucl Med 1993; 34: 609-613.
57. Alakurtti K, Aalto S, Johansson JJ, Nagren K, Tuokkola T, Oikonen V et al. Reproducibility of striatal and thalamic dopamine D2 receptor binding using [11C] raclopride with high-resolution positron emission tomography. J Cereb Blood Flow Metab 2011; 31: 155-165.
58. Riksen NP, Rongen GA, Smits P. Acute and long-term cardiovascular effects of coffee: Implications for coronary heart disease. Pharmacol Ther 2009; 121: 185-191.